CIK 0000887359
- Large accelerated filer
Vericel Corp
Sign in to watch- Ticker
- VCEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- MI
- Entity type
- Operating
- EIN
- 943096597
- Phone
- +1 617-588-5555
- Business address
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Former names
- AASTROM BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,896,581
- in 8 filings, $5.8M under 10b5-1 plans
Net −$5,896,581. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Mara Joseph Anthony Jr −$4.1M Chief Financial Officer sold 82% of stake
- Flynn Sean C. −$779K Chief Legal Officer sold 88% of stake
- MCLAUGHLIN KEVIN F −$413K Director sold 28% of stake
- ZERBE ROBERT L MD −$386K Director sold 19% of stake
- SIEGAL JONATHAN −$188K Principal Accounting Officer sold 73% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-09 | ZERBE ROBERT L MD Director | Exercise or conversion 10b5-1 | +2,000 | $13.05 | $26K | 34,995 |
| 2026-11-09 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,000 | $57.88 | $116K | 32,995 |
| 2026-11-09 | ZERBE ROBERT L MD Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | +2,000 | 0 | ||
| 2026-11-05 | ZERBE ROBERT L MD Director | Exercise or conversion 10b5-1 | +500 | $13.05 | $7K | 33,495 |
| 2026-11-05 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −500 | $55.00 | $28K | 32,995 |
| 2026-11-05 | ZERBE ROBERT L MD Director | Exercise or conversion 10b5-1 | +2,500 | $13.05 | $33K | 35,495 |
| 2026-11-05 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,500 | $51.67 | $129K | 32,995 |
| 2026-11-05 | ZERBE ROBERT L MD Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | +500 | 4,500 | ||
| 2026-11-05 | ZERBE ROBERT L MD Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | +2,500 | 2,000 | ||
| 2026-11-04 | ZERBE ROBERT L MD Director | Exercise or conversion 10b5-1 | +2,500 | $13.05 | $33K | 35,495 |
| 2026-11-04 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,500 | $45.40 | $114K | 32,995 |
| 2026-11-04 | ZERBE ROBERT L MD Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | +2,500 | 5,000 | ||
| 2026-04-29 | ZERBE ROBERT L MD Director | Exercise or conversion | +3,200 | 32,995 | ||
| 2026-04-29 | ZERBE ROBERT L MD Director | Exercise or conversion · Restricted Stock Unit | +3,200 | 0 | ||
| 2026-04-29 | ZERBE ROBERT L MD Director | Grant or award · Stock Option (Right to Buy) | +8,000 | 8,000 | ||
| 2026-04-29 | ZERBE ROBERT L MD Director | Grant or award · Restricted Stock Unit | +3,200 | 3,200 | ||
| 2025-04-30 | ZERBE ROBERT L MD Director | Exercise or conversion | +3,200 | 29,795 | ||
| 2025-04-30 | ZERBE ROBERT L MD Director | Exercise or conversion · Restricted Stock Unit | +3,200 | 0 | ||
| 2025-04-30 | ZERBE ROBERT L MD Director | Grant or award · Stock Option (Right to Buy) | +8,000 | 8,000 | ||
| 2025-04-30 | ZERBE ROBERT L MD Director | Grant or award · Restricted Stock Unit | +3,200 | 3,200 |
Page 1 of 5 · 100 trades